Yun Kang
Union Hospital
Wuhan, 430022, China
Wuhan, 430022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-analysis.
Journal: Blood cancer journal
Published: January 31, 2026
Comparison of regional differences in safety and efficacy of CAR-T therapy for hematologic malignancies in a real-world setting: a systematic review and meta-analysis.
Journal: Critical reviews in oncology/hematology
Published: August 24, 2025
Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2025
BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial.
Journal: Cancer medicine
Published: March 25, 2025
Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Journal: Journal of hematology & oncology
Published: January 24, 2024
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Journal: Leukemia
Published: August 15, 2023
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.
Journal: Blood cancer journal
Published: November 23, 2022
Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Journal: Cytotherapy
Published: November 12, 2022
Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.
Journal: British journal of haematology
Published: August 15, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026